Search results for " CARDIOVASCULAR DISEASE"

showing 10 items of 179 documents

Resveratrol: preventing properties against vascular alterations and ageing.

2005

International audience; Cardiovascular diseases are the leading cause of death in developed countries where the common pathological substrate underlying this process is atherosclerosis. Several new concepts have emerged in relation to mechanisms that contribute to the regulation of the vascular diseases and associated inflammatory effects. Recently, potential antioxidants (vitamin E, polyphenols) have received much attention as potential anti-atherosclerotic agents. Among the polyphenols with health benefic properties, resveratrol, a phytoalexin of grape, seem to be a good candidate protecting the vascular walls from oxidation, inflammation, platelet aggregation, and thrombus formation. In …

MESH : Oxidative StressAgingAntioxidantPlatelet AggregationArteriosclerosismedicine.medical_treatmentResveratrolPharmacologymedicine.disease_causeMuscle Smooth Vascularchemistry.chemical_compoundMESH : VasodilationMESH : Foam CellsMESH : Platelet AggregationStilbenesMESH : Cardiovascular DiseasesMESH : Macrophageschemistry.chemical_classificationNeovascularization PathologicPhytoalexinfood and beveragesVasodilationBiochemistryCardiovascular Diseasesmedicine.symptomBiotechnologyLipoproteinsInflammationHealth PromotionMESH : LipoproteinsBiologyMESH : StilbenesMESH : ArteriosclerosismedicineHumans[ SDV.BBM ] Life Sciences [q-bio]/Biochemistry Molecular BiologyReactive oxygen speciesMechanism (biology)MacrophagesMESH : HumansMESH : Neovascularization PathologicMESH : Muscle Smooth VascularMESH : AgingOxidative StresschemistryAgeingResveratrolMESH : Health PromotionOxidative stressFood ScienceFoam Cells
researchProduct

Lipidomic profiling identifies signatures of metabolic risk

2020

Background: Metabolic syndrome (MetS), the clustering of metabolic risk factors, is associated with cardiovascular disease risk. We sought to determine if dysregulation of the lipidome may contribute to metabolic risk factors. Methods: We measured 154 circulating lipid species in 658 participants from the Framingham Heart Study (FHS) using liquid chromatography-tandem mass spectrometry and tested for associations with obesity, dysglycemia, and dyslipidemia. Independent external validation was sought in three independent cohorts. Follow-up data from the FHS were used to test for lipid metabolites associated with longitudinal changes in metabolic risk factors. Results: Thirty-nine lipids were…

Male0301 basic medicineResearch paperdhSL dihydrosphingolipidBMI body mass indexlcsh:MedicineATHEROGENIC LIPOPROTEINSBioinformaticsFHS Framingham Heart StudyPC phosphatidylcholinePESA Progression of Early Subclinical Atherosclerosis0302 clinical medicineFramingham Heart StudyRisk FactorsSAFHS San Antonio Family Heart StudyLC-MS/MS liquid chromatography-tandem mass spectrometryMedicineLongitudinal StudiesMetabolic riskPLASMA SPHINGOLIPID METABOLISMPOPULATIONlcsh:R5-920education.field_of_studySPHINGOMYELINCE cholesteryl esterDysglycemiaGeneral MedicineMiddle AgedLipidomePS phosphatidylserineCardiovascular diseaseLipidsMetabolic syndrome3. Good healthCARDIOVASCULAR-DISEASE030220 oncology & carcinogenesisHEARTMetS metabolic syndromeFemaleDisease SusceptibilityLGPL lysoglycerophospholipidSL sphingolipidlcsh:Medicine (General)LPE lysophosphatidylethanolamineAdultFDR false discovery rateTAG triacylglycerolPopulationCer ceramideCVD cardiovascular diseasePE phosphatidylethanolamineDENSITY-LIPOPROTEINRisk AssessmentGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesAnimalsHumanseducationT2DM type II diabetes mellitusAgedLPC lysophosphatidylcholineSM sphingomyelinbusiness.industryCERAMIDElcsh:RHDL-C High density lipoprotein cholesterolBiomarkerLipid Metabolismmedicine.diseaseObesitySphingolipidCross-Sectional Studies030104 developmental biologyDyslipidemiaERF Erasmus Family StudyLipidomicsMetabolic syndromeINDUCED INSULIN-RESISTANCEbusinessDAG diacylglycerolBody mass indexBiomarkersDyslipidemiaMRM multiple reaction monitoringFASTING GLUCOSE
researchProduct

Dietary inflammatory index and mortality: a cohort longitudinal study in a Mediterranean area

2020

Background: Higher Dietary Inflammatory Index (DII®) scores are associated with increased morbidity and mortality. However, little is known about the effects of DII on mortality in Mediterranean countries. Therefore, in the present study, we aimed to investigate the potential association between DII scores and overall, cancer and cardiovascular disease (CVD) mortality in people living in a Mediterranean area. Methods: DII scores were calculated using a validated food-frequency questionnaire. DII scores were then categorised into tertiles. Mortality was ascertained via death certificates. The association between DII scores with overall and cause-specific mortality was assessed via a multivar…

Male0301 basic medicinemedicine.medical_specialtyLongitudinal studyMedicine (miscellaneous)030209 endocrinology & metabolismDiseaseDiet Surveys03 medical and health sciencescancer; cardiovascular disease; dietary inflammatory index; mortality0302 clinical medicinecardiovascular diseaseCause of DeathNeoplasmsInternal medicinemedicineHumanscancerLongitudinal StudiesAgedProportional Hazards ModelsInflammation030109 nutrition & dieteticsNutrition and DieteticsMediterranean Regionbusiness.industryHazard ratioConfoundingMiddle AgedmortalityConfidence intervalIncreased riskCardiovascular DiseasesCohortdietary inflammatory indexRegression AnalysisMediterranean areaFemalesense organsDiet HealthybusinessJournal of Human Nutrition and Dietetics
researchProduct

A Periodic Diet that Mimics Fasting Promotes Multi-System Regeneration, Enhanced Cognitive Performance, and Healthspan

2015

SummaryProlonged fasting (PF) promotes stress resistance, but its effects on longevity are poorly understood. We show that alternating PF and nutrient-rich medium extended yeast lifespan independently of established pro-longevity genes. In mice, 4 days of a diet that mimics fasting (FMD), developed to minimize the burden of PF, decreased the size of multiple organs/systems, an effect followed upon re-feeding by an elevated number of progenitor and stem cells and regeneration. Bi-monthly FMD cycles started at middle age extended longevity, lowered visceral fat, reduced cancer incidence and skin lesions, rejuvenated the immune system, and retarded bone mineral density loss. In old mice, FMD c…

MaleAbdominal Fat; Adult; Aged; Aging; Animals; Body Weight; Cardiovascular Diseases; Diet; Female; Humans; Male; Mice; Mice Inbred C57BL; Middle Aged; Neoplasms; Neurogenesis; Pilot Projects; Psychomotor Performance; Regeneration; Saccharomyces cerevisiae; Young Adult; Cognition; Fasting; LongevityAgingPhysiologyPilot ProjectsMiceCognitionNeoplasmsCardiovascular DiseaseSettore MED/49 - Scienze Tecniche Dietetiche Applicatemedia_common2. Zero hungerNeurogenesisLongevityFastingMiddle Aged3. Good healthCardiovascular DiseasesFemaleStem cellHumanAdultmedicine.medical_specialtyNeurogenesismedia_common.quotation_subjectLongevityAbdominal FatSaccharomyces cerevisiaeBiologyArticleYoung AdultImmune systemInternal medicineDiabetes mellitusmedicineAnimalsHumansRegenerationPilot ProjectAdverse effectCell Biology; Molecular Biology; PhysiologyMolecular BiologyAgedAnimalBody WeightCell Biologymedicine.diseaseMiddle ageDietMice Inbred C57BLEndocrinologyCancer cellNeoplasmNeurogenesiPsychomotor Performance
researchProduct

Knee osteoarthritis and risk of hypertension: A longitudinal cohort study

2018

Whilst previous research has indicated an association between osteoarthritis and cardiovascular disease, it remains unclear whether people with osteoarthritis are at greater risk of developing hypertension. The aim of this study was to answer this uncertainity. We used the data of the Osteoarhritis Iniative, an ongoing public and private longitudinal study including people at higher risk of osteoarthritis or having knee osteoarthritis. Knee osteoarthritis was defined through radiological and clinical assessment. Incident hypertension was defined as a systolic blood pressure >140 mmHg and/or a diastolic value >90 mmHg. Multivariate Cox’s regression analyses were constructed where the p…

MaleAgingLongitudinal studymedicine.medical_specialtySystoleDiastoleBlood PressureOsteoarthritisDisease03 medical and health sciences0302 clinical medicineDiastoleRisk FactorsInternal medicineEpidemiologyHumansMedicineLongitudinal Studies030212 general & internal medicineSystoleAged030203 arthritis & rheumatologybusiness.industryIncidence (epidemiology)Original ArticlesMiddle AgedOsteoarthritis Kneemedicine.diseaseBlood pressureHypertensionFemaleGeriatrics and Gerontologybusinessosteoarthritis hypertension cardiovascular disease epidemiologyFollow-Up Studies
researchProduct

Higher intracoronary attenuation improves diagnostic accuracy in MDCT coronary angiography

2006

OBJECTIVE: The purpose of this study was to investigate whether the amount of intracoronary attenuation influences the diagnostic accuracy of MDCT coronary angiography in the detection of clinically significant stenosis. MATERIALS AND METHODS: One hundred twenty patients in sinus rhythm with suspected coronary artery disease who underwent MDCT of the heart and conventional coronary angiography were retrospectively selected. The population was divided into two groups depending on median (326 H) coronary vascular enhancement (i.e., low attenuation and high attenuation). The diagnostic accuracy of MDCT for the detection of clinically significant coronary artery lesions (> or = 50% lumen reduct…

MaleCoronary angiographymedicine.medical_specialtycardiac imaging cardiovascular disease contrast media CT coronary arteriographyPopulationLumen (anatomy)Coronary AngiographySensitivity and SpecificityAngina PectorisCoronary artery diseasePredictive Value of TestsmedicineHumansRadiology Nuclear Medicine and imagingSinus rhythmeducationCardiac imagingeducation.field_of_studybusiness.industryAttenuationCoronary StenosisGeneral MedicineMiddle Agedmedicine.diseaseRadiographic Image Enhancementmedicine.anatomical_structureFemaleRadiologyTomography X-Ray ComputedbusinessArteryAmerican Journal of Roentgenology
researchProduct

Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately …

2017

Background The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone fails to achieve adequate glycaemic control is debated. We aimed to compare the long-term effects of pioglitazone versus sulfonylureas, given in addition to metformin, on cardiovascular events in patients with type 2 diabetes. Methods TOSCA.IT was a multicentre, randomised, pragmatic clinical trial, in which patients aged 50–75 years with type 2 diabetes inadequately controlled with metformin monotherapy (2–3 g per day) were recruited from 57 diabetes clinics in Italy. Patients were randomly assigned (1:1), by permuted blocks randomisation (block size 10), stratified by site and…

MaleDiabetes and Metabolism ipoglycemic drugs cardiovascualr eventSettore MED/09 - Medicina Internaendocrine system diseasesIMPACTpioglitazone versus sulfonylureasEndocrinology Diabetes and MetabolismGLIMEPIRIDEDiabetes cardiovascular events metformin pioglitazone sulphonylureasType 2 diabetes030204 cardiovascular system & hematologyInternal Medicine; Endocrinology Diabetes and Metabolism; Endocrinologylaw.inventionSettore MED/13 - EndocrinologiaGlibenclamide0302 clinical medicineRandomized controlled triallawGLYCEMIC CONTROLGliclazideInternal medicinediabetes and metabolismRISKeducation.field_of_studydiabetesIncidenceInternal medicine; endocrinology diabetes and metabolism; endocrinologyMiddle AgedINSULINMetforminMetforminTreatment OutcomeEditorialsulphonylureasCardiovascular DiseasesCombinationDrug Therapy CombinationFemaleType 2medicine.drugmedicine.medical_specialtyPopulation030209 endocrinology & metabolismAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Drug Therapy Combination; Female; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Pioglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment OutcomeCardiovascular events03 medical and health sciencesendocrinologyGLUCOSE-LOWERING DRUGSDrug TherapyInternal medicineDiabetes MellitusmedicineHumansHypoglycemic AgentssulfonylureaseducationTOSCA.ITAgedPioglitazonebusiness.industryMORTALITYnutritional and metabolic diseasesInsulin resistancemedicine.diseaseSurgeryGlimepirideSulfonylurea CompoundsDiabetes Mellitus Type 2Diabetes Mellitus; Pioglitazone; Insulin resistanceThiazolidinedionesbusinessFOLLOW-UPPioglitazone
researchProduct

Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings f…

2020

Background and aims There is poor knowledge on characteristics, comorbidities and laboratory measures associated with risk for adverse outcomes and in-hospital mortality in European Countries. We aimed at identifying baseline characteristics predisposing COVID-19 patients to in-hospital death. Methods and results Retrospective observational study on 3894 patients with SARS-CoV-2 infection hospitalized from February 19th to May 23rd, 2020 and recruited in 30 clinical centres distributed throughout Italy. Machine learning (random forest)-based and Cox survival analysis. 61.7% of participants were men (median age 67 years), followed up for a median of 13 days. In-hospital mortality exhibited a…

MaleEpidemiologyEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologycomputer.software_genreMachine Learning0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseEpidemiology80 and overMedicineAge FactorViralHospital MortalityBetacoronavirus Hospital MortalityYoung adultAged 80 and overNutrition and DieteticsCOVID-19; Epidemiology; In-hospital mortality; Risk factorsMortality rateHazard ratioAge FactorsMiddle AgedIn-hospital mortalityC-Reactive ProteinCardiovascular DiseasesFemaleSurvival AnalysiCardiology and Cardiovascular MedicineCoronavirus InfectionsHumanGlomerular Filtration RateAdultmedicine.medical_specialtyAdolescentPneumonia Viral030209 endocrinology & metabolismSettore MED/17 - MALATTIE INFETTIVEMachine learningCOVID-19; Epidemiology; In-hospital mortality; Risk factors; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; C-Reactive Protein; COVID-19; Cardiovascular Diseases; Coronavirus Infections; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Pandemics; Pneumonia Viral; Retrospective Studies; Risk Factors; SARS-CoV-2; Survival Analysis; Young Adult; Betacoronavirus; Hospital Mortality; Machine LearningArticle03 medical and health sciencesBetacoronavirusYoung AdultHumansRisk factorPandemicsSurvival analysisAgedRetrospective StudiesPandemicBetacoronavirubusiness.industryCoronavirus InfectionSARS-CoV-2Risk FactorCOVID-19Retrospective cohort studyPneumoniaSurvival AnalysisConfidence intervalRisk factorsArtificial intelligencebusinesscomputerNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct

Liraglutide and cardiovascular outcomes in type 2 diabetes

2016

The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown. METHODS In this double-blind trial, we randomly assigned patients with type 2 diabetes and high cardiovascular risk to receive liraglutide or placebo. The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary hypothesis was that liraglutide would be noninferior to placebo with regard to the primary outcome, with a margin of 1.30 for the upper boundary of the 95% confidence interval of the hazard ratio. No adjus…

MaleGastrointestinal DiseasesTreatment outcomeClinical BiochemistryMyocardial InfarctionType 2 diabetes030204 cardiovascular system & hematologylaw.inventionMedicine; Endocrinology0302 clinical medicineRandomized controlled trialAged; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Myocardial Infarction; Stroke; Treatment Outcome; Medicine (all)lawCardiovascular DiseaseClinical-trial; Pancreatitis; Therapies; Cancer; Drugs11 Medical and Health SciencesResearch Support Non-U.S. Gov'tMedicine (all)PANCREATITISHazard ratioLEADER Steering CommitteeFollow up studiesGeneral MedicineMiddle AgedAlbiglutideMulticenter StudyStrokeTRIALSTreatment OutcomeCardiovascular DiseasesRandomized Controlled TrialFemaleLife Sciences & BiomedicineCardiovascular outcomesmedicine.drugHumanmedicine.medical_specialtyGastrointestinal DiseaseMEDLINE030209 endocrinology & metabolismLEADER Trial InvestigatorsPlaceboFollow-Up Studie03 medical and health sciencesMedicine General & InternalResearch Support N.I.H. ExtramuralDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicinemedicineJournal ArticleHumansHypoglycemic AgentsAgedGlycemic efficacyScience & TechnologyHypoglycemic AgentLiraglutidebusiness.industrySemaglutideLiraglutidemedicine.diseaseSurgeryDiabetes Mellitus Type 2businessFollow-Up Studies
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct